Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has made a significant addition to its board of directors with the appointment of David E. I. Pyott, the former Chairman and CEO of Allergan, Inc. Pyott brings a wealth of experience, having led Allergan through a transformative period, growing its revenue from approximately $1 billion to over $7 billion during his 17-year tenure as CEO.
Pyott's leadership at Allergan earned him recognition as one of the "100 best performing CEOs in the world" by Harvard Business Review. His extensive industry experience also includes roles at Novartis, where he headed the nutrition division and served on the executive committee.
Tarsus Pharmaceuticals, known for its focus on revolutionizing treatment, has already achieved significant milestones with its lead commercial product, Xermelo (telotristat ethyl), and a promising pipeline. The company is currently advancing its pipeline to address diseases with high unmet needs across therapeutic categories, including eye care, dermatology, and infectious disease prevention.
Tarsus' FDA-approved product, Xermelo (telotristat ethyl), has shown positive growth with a 15% increase in sales compared to the previous quarter. Additionally, the company's pipeline includes TP-04 for potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in phase 2 development.
With the addition of David E. I. Pyott to its board of directors, Tarsus Pharmaceuticals is poised for sustained growth and further meaningful innovation in the field of eye care and beyond. Following these announcements, the company's shares moved -3.41%, and are now trading at a price of $71.14. For more information, read the company's full 8-K submission here.
